Phase III, Randomized, Open-label, Global, Multicenter Study of Rilvegostomig or Durvalumab in Combination With Chemotherapy as a First-line Treatment for Patients With Advanced Biliary Tract Cancer (ARTEMIDE-Biliary02).
Germany, Poland, Italy, Belgium, France, Netherlands, Spain
Condition studied
Biliary Tract Cancer
Investigational medicinal product(s)
GEMCITABINEIMFINZI 50 mg/mL concentrate for solution for infusionINFLIXIMABCISPLATINMYCOPHENOLATE MOFETILRilvegostomig
Eligibility
Age group
18-64 years, 65+ years
Sex
Female, Male
Primary endpoint
Overall survival of Rilvegostomig+Chemotherapy vs Durvalumab+Chemotherapy
Endpoint detail
Progression Free Survival of Rilvegostomig+Chemotherapy vs Durvalumab+Chemotherapy
Official registry record
This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.